Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing.

Elsayegh, Nisreen; Barrera, Angelica M Gutierrez; Muse, Kimberly I; Lin, Heather; Kuerer, Henry M; Helm, Monica; Litton, Jennifer K; Arun, Banu K

Elsayegh, Nisreen; Barrera, Angelica M Gutierrez; Muse, Kimberly I; Lin, Heather; Kuerer, Henry M; Helm, Monica; Litton, Jennifer K; Arun, Banu K.

Afiliação

Elsayegh N; Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Barrera AM; Departments of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Muse KI; Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Lin H; Biostatistics, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Kuerer HM; Surgical Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Helm M; Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Litton JK; Departments of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Arun BK; Clinical Cancer Genetics, The University of Texas MD Anderson Cancer CenterHouston, TX, USA; Departments of Breast Medical Oncology, The University of Texas MD Anderson Cancer CenterHouston, TX, USA.

Front Genet ; 7: 71, 2016.

Article em En | MEDLINE | ID: mdl-27200080

Palavras-chave

BRC; BRCA mutation status; BRCA1; BRCAPRO; ductal carcinoma in situ (DCIS); gene; genes; genetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google